Webinar :Register now for webinar on 'Trade BankNifty in just 15 minutes a day' - By Asmita Patel
Last Updated : Oct 09, 2020 04:57 PM IST | Source: Moneycontrol.com

Russia likely to register a second COVID-19 vaccine on October 15: Developer

The vaccine has been developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last month.

Russia is expected to register a second potential vaccine against COVID-19 on October 15, the vaccine’s developer said on October 9.

The vaccine has been developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last month.

Russia will begin Phase III trials of a second potential vaccine against COVID-19, developed by Siberia's Vector Institute, in November-December, the TASS news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on October 2.


"The clinical trials have been very successful. The volunteers are developing the necessary titers and no one has any clinical signs after the vaccine - neither temperature nor any other reaction," Russia’s chief sanitary doctor Anna Popova said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

"There are not many such vaccines in the world, which are being developed by the Vector Center. This is a rather complicated process," Popova told TASS.

The Indian pharma giant has collaborated with The Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.

With inputs from Reuters
First Published on Oct 9, 2020 04:57 pm